You are currently viewing a new version of our website. To view the old version click .
Genes
  • Review
  • Open Access

20 September 2021

p53 mRNA Metabolism Links with the DNA Damage Response

,
,
,
and
1
Department of Medical Biosciences, Umeå University, 901-87 Umeå, Sweden
2
RECAMO, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656-53 Brno, Czech Republic
3
Inserm UMRS1131, Institut de Genetique Moleculaire, Universite Paris 7, Hopital St Louis, F-75010 Paris, France
4
International Centre for Cancer Vaccine Science, University of Gdansk, 80-822 Gdansk, Poland
This article belongs to the Special Issue Reciprocal Links between RNA Metabolism and DNA Damage

Abstract

Human cells are subjected to continuous challenges by different genotoxic stress attacks. DNA damage leads to erroneous mutations, which can alter the function of oncogenes or tumor suppressors, resulting in cancer development. To circumvent this, cells activate the DNA damage response (DDR), which mainly involves cell cycle regulation and DNA repair processes. The tumor suppressor p53 plays a pivotal role in the DDR by halting the cell cycle and facilitating the DNA repair processes. Various pathways and factors participating in the detection and repair of DNA have been described, including scores of RNA-binding proteins (RBPs) and RNAs. It has become increasingly clear that p53’s role is multitasking, and p53 mRNA regulation plays a prominent part in the DDR. This review is aimed at covering the p53 RNA metabolism linked to the DDR and highlights the recent findings.

1. Introduction

DNA Damage Processes and Repair Mechanisms
The maintenance of genome integrity is essential for the precise transfer of genetic information. This is being constantly challenged by a range of insults to the cell such as intrinsic (error in replication and reactive oxygen species) or extrinsic cues (chemicals, UV light, ionizing radiations and chemotherapeutic drugs), leading to DNA damage [1,2]. All of these extrinsic and intrinsic attacks lead to the generation of DNA lesions, which include modified bases, mismatches, strand breaks and the crosslink of strands [3,4]. To revert the DNA damage, mammalian cells have developed a sophisticated network of molecular signaling pathways collectively described as the DNA damage response (DDR); each of these pathways repairs a specific type of DNA damage (reviewed in Reference [5]). Briefly, DDR is a multistep phosphorylation-driven signaling cascade, which coordinates the damage recognition, DNA repair processes and cell cycle regulation to ensure the genome integrity. The components involved in DDR are grouped as damage sensors, damage transducers and damage effectors. The damage sensors are activated and recruited to the damage site based on the nature of the damage. Double-stranded breaks (DSBs) are sensed by the MRE11/RAD50/NBS1 (MRN) complex, which recruits and activates ataxia–telangiectasia-mutated (ATM) kinase, which further transduces and activates the damage effectors by a series of phosphorylation events. Besides this, the ATM kinase interacts with Nibrin (NBS1) and phosphorylates H2A histone family member X (γ-H2AX) at serine 139; phosphorylated γ-H2AX functions as a damage sensor and activates transducers [6]. Single-stranded breaks (ssDNA damage) are sensed by replication protein A (RPA) and the RAD9/RAD1/HUS1 complex and activates the Rad3-related (ATR) pathway.
Three protein kinases, DNA-dependent protein kinase (DNA-PK), ATM and ATR, are members of the phosphoinositide 3 kinase-related protein kinases (PI3KKs) family, sharing a similar functional domain organization. The ATM kinase is mainly involved in DSBs. The ATR kinase is involved in a broad spectrum of DDR, such as ssDNA damage, DSBs and a variety of DNA lesions generated during DNA replication; thus, the ATR kinase is essential for cell survival. DNA-PK involved in DSBs and in multiple DNA repair pathways, apart from DDR DNA-PK also functions in cell cycle progression, telomere maintenance and transcription regulation. Upon activation, these kinases phosphorylate a series of overlapping substrate pools to facilitate DNA repair and coordinate cell cycle regulation. The ATM and ATR kinases serve as the key signaling factors in DDR; two of the best-researched targets of the ATM and ATR kinases are checkpoint kinase 2 (CHK2) and checkpoint kinase 1 (CHK1), which function together with the ATM/ATR kinases in activating and regulating the effectors. The DDR effectors are substrates of the DDR kinases that, upon activation, participate in a range of cellular processes such as DNA repair, cell cycle control, apoptosis and senescence to ensure the genome integrity (Figure 1) (reviewed in [7,8,9,10]).
Figure 1. Overview of the DDR and p53 functional roles. Upon DNA damage, the damage sensor proteins sense the DNA lesions, recruit and activate the cascade of transducers, which, in turn, activate the DNA damage effectors that exert an appropriate response to fix the damage and maintain the genome integrity. Double-stranded DNA breaks (DSBs) are sensed by the MRN complex and fixed by the ATM/DNA-PK kinase-mediated response pathway. Single-stranded breaks (ssDNA) are sensed by the RPA and RAD complex, which activates the ATR kinase-mediated response. BRCA1—Breast cancer type 1 susceptibility protein, MDC1—Mediator of DNA damage checkpoint protein 1, 53BP1—p53-binding protein 1, TopBP1—DNA Topoisomerase II-Binding Protein 1, ATRIP—ATR interacting protein, POLK—DNA Polymerase Kappa, XPC—DNA repair protein complementing XP-C cells, GADD45A—Growth Arrest and DNA Damage Inducible α, PLK4—Polo-Like Kinase 4, BAX—Bcl-2-associated X protein, NOXA—Phorbol-12-myristate-13-acetate-induced protein 1, PUMA—p53 upregulated modulator of apoptosis, PML—Promyelocytic leukemia protein and PAI-1—Plasminogen activator inhibitor-1.
Depending on the extent of damage, cells respond either by arresting the progression of the cell cycle and allowing the DNA repair process to fix the damage or evoke cellular senescence or apoptosis if the damage is too severe [11,12]. The DDR is composed of a repertoire of DNA repair pathways, each of which acts based on the nature of damage inflicted. For example, DNA double-stranded breaks are repaired via either homologous recombination (HR) or by nonhomologous end-joining (NHEJ). Mismatches induced by replication errors are corrected by mismatch repair (MMR), small DNA lesions are repaired by base-excision repair (BER) and large nucleotide adducts are corrected by the nucleotide excision repair (NER) pathway. These pathways are not fixed per se; some of the proteins often participate in multiple DDR pathways (reviewed in References [4,11,13,14,15,16,17]).
The failure or erroneous repair of DNA lesions leads to mutations, aberrant gene expressions and chromosomal rearrangements, which pave the way for multiple diseases such as neurodegenerative disorders, aging, immune deficiencies and several types of cancers. Indeed, the prevalence of genomic instability and mutations are still the hallmark of many types of cancers, and the genes controlling DDR components are highly mutated and dysregulated in cancers [11,18].

2. p53 Functional Roles in DNA Damage

The p53 tumor suppressor protein was first discovered as a host protein bound to Simian virus 40 large T antigen (SV40) in virus-transformed cells [19,20]. TP53 is the most frequently mutated gene in many cancers, and its mutations are highly correlated with the poor prognosis of cancer patients [21,22]. p53 is functionally activated in response to several cellular stress stimuli, such as DNA damage, unfolded protein response (UPR), nutrient deficiency and hypoxia [23,24,25,26]. Though vastly regarded as a tumor suppressor protein, p53 also confers pro-survival and oncogenic activities via gain-of-function mutations [27]. p53 is considered as a ‘guardian of the genome’ and orchestrates a variety of DDR pathways and forms the critical link between the DNA damage responses and tumor suppression[18,28,29]. Numerous studies have demonstrated p53-dependent cell cycle arrest and apoptosis in response to DNA damage. Several cellular, as well as animal, models lacking functionally active p53 showed defects in response to DNA damage and tumor suppression (reviewed in References [30,31]). For example, mice lacking p53 are highly prone to cancer, and patients suffering from Li-Fraumeni syndrome, due to germline TP53 mutations, are at high risk for the early development of multiple tumors [12,32]. The identification of p53′s role in DNA damage dates back to the early 1990s, where multiple studies showed the upregulation of p53 protein levels by DNA damage-inducing agents (ultraviolet light (UV), ionizing radiations and chemotherapeutic agents) [18,33,34,35,36]. Subsequent studies showed that most cellular stress stimuli lead to p53 activation. In addition to its upregulation, p53 is also modified upon DNA damage—in particular, the phosphorylation of serine 15 by the ATM and ATR kinases, a well-established readout of p53 activation during DNA damage (reviewed in Reference [7]). Additionally, DNA-PK phosphorylates p53 at serine 15 and serine 37 residues and activates it by preventing the binding of MDM2 [37]. Following activation, p53 promotes cell cycle arrest at the G1 checkpoint by transcriptionally activating several cell cycle regulatory factors such as the p21 cyclin-dependent kinase inhibitor, thereby facilitating DNA repair and continuing cell division [38,39]. In some cases, p53 also promotes irreversible senescence or apoptosis mediated by several proapoptotic factors, including B-cell lymphoma 2 (Bcl-2), following DNA damage [35,40,41]. So far, it is not well-understood why p53 causes cell cycle arrest or apoptosis, and several factors and contexts contributing towards this discrepancy are detailed in the review by Kastenhuber and Lowe [22]. Furthermore, p53 has essential roles in several DNA repair processes, such as nucleotide excision repair and base excision repair, by activating/regulating the target genes of DNA repair machineries. Both transcription-dependent and -independent functions of p53 are accounted to regulate DNA repair pathways. The diverse functional roles of p53 in each DNA repair process are reviewed in detail by Williams and Schumacher [3].

4. Overview of RBPs Linked with the DDR and Functional Interplay with p53

Recent advancements with large-scale genomic and proteomic studies have led to the discovery of numerous RBPs as key players in the DDR. The functional roles of RNA and RBPs in DDR and DNA repair processes are increasingly emerging, with numerous reports suggesting DDR processes are linked with post-transcriptional gene regulation [93,94,95]. RBPs, together with several ncRNAs, are envisaged to play diverse roles in the DDR. Several RBPs are reported to act directly at the site of DNA damage and facilitate DNA repair processes by interplaying with multiple DNA repair proteins and, also, with p53 (Table 2 provides the brief overview of RBPs associated with the DDR and their functional interplay with p53). For example, hnRNP C and hnRNP UL 1 and 2 are binding partners of DNA repair complexes BRCA1/BRCA2/PALB2 and MRN, respectively, and play essential roles in promoting ATR-dependent signaling and HR-mediated repair [93,94]. RNA-binding motif protein (RBM) X binds to dsDNA breaks and protects them from degradation, thereby increasing the fidelity of the repair [94]. FUS and NONO are recruited to dsDNA break sites in a PAR-dependent manner and are involved in NHEJ and HR. Prp19 is a ubiquitin ligase involved mainly in splicing and is reported to localize the DNA damage site via binding to RPA and facilitate the ATR response [93]. Recently, RBM14 was reported to interact with Ku80 and participate in the NHEJ DNA repair pathway. Interestingly, RNA binding does not account for the recruitment of several RBPs to the DNA damage site, suggesting that these RBPs are recruited either by interacting with the DNA template or via DNA repair proteins [94].
Table 2. Overview of RNA binding proteins (RBPs) linked with the DDR and functional interplay with p53.
Apart from the direct roles in DDR, RBPs also play a key role in regulating the gene expression of DDR and checkpoint proteins at both transcriptional and post-transcriptional processes (reviewed in References [94,95,129]). RBPs also bind to an increasing number of long noncoding RNAs (lncRNAs) and, together, orchestrate transcription and chromatin remodeling processes [94]. The role of multiple RBPs in regulating p53 expression during DNA damage was already discussed above. Additionally, many RBPs have been reported to play a key role in preventing DNA damage by controlling R-loop (three stranded nucleic acid structures consist of a DNA–RNA hybrid and unpaired single-stranded DNA) formation and DNA breaks [130].
Consequently, using functional screens and proteomic studies, DNA damage-signaling proteins are identified to post-translationally modify several RNA-processing factors, including RBPs [94]. Many RBPs are directly phosphorylated by DDR signaling kinases such as ATM, ATR, DNA-PK (sensors) CHK1 and CHK2 (transducers); this regulates the RBP activities in DNA damage. Apart from phosphorylation, RBPs are also modified by poly (ADP-ribosylation) or parylations and acetylations. DNA damage-signaling pathways are also reported to highly modulate the subcellular localization and abundance of many RBPs during DNA damage (reviewed in Reference [94]).

5. Conclusions and Perspectives

Despite being intensively researched for many years, p53 still remains a central candidate of interest in the cancer research field with its ever-emerging functional roles in multiple cellular processes. There are still many questions left unanswered about its regulated activity under different cellular stresses. p53 mRNA regulation has become one of the important facets in the functional activation of p53 in response to various cellular stress conditions. In the DDR, p53 mRNA plays a pivotal role in p53 activation. Many RBPs, including transacting translation factors and microRNAs, were identified to bind multiple regions of p53 mRNA and regulate its translation. It is likely that more such factors will be uncovered in the near future. However, it is unclear whether these factors coordinate in regulating p53 activation during DNA damage. If they function together, it remains to be seen how these factors coordinate to orchestrate p53 mRNA translation. So far, the molecular mechanism of some of these factors have been well-established with multiple RNA–protein biochemical techniques and functional studies. The molecular action of other p53 mRNA-binding factors during DNA damage need to be studied in detail.
The ATM kinase activates p53 during DNA damage; it is interesting to note that ATM regulates both the folding of nascent p53 mRNA as well as the encoding nascent peptide. It will be fascinating to know if this represents a broader model of how signaling pathways integrate the synthesis and degradation of a protein. In line with this, it would be interesting to see how signaling pathways regulate individual mRNA translations under certain cellular stress conditions. It will be a likely scenario that the structural rearrangement of p53 mRNA during DNA damage contributes to its translation regulation and the binding of various proteins. Future studies should focus on determining the native p53 RNA structure under different stress conditions and identifying the protein contact points in p53 RNA. Emerging observations indicate a potential linkage and functional dependence between the post-transcriptional modifications of mRNA and their structures; it will be interesting to investigate such modifications in p53 mRNA and their regulatory roles in p53 gene expression.
Recent observation based on CRISPR-Cas9 knockdown have indicated that the endogenous p53 levels are not reliant on regulation by p53 3′ UTR [84]; these results are intriguing and, at the same time, strengthen the regulatory roles of the p53 mRNA coding sequence. Similar studies should be done to access the functional role p53 5′ UTR in regulating the endogenous p53 levels.

Author Contributions

S.V.G. conceived the content, assembled the figures and wrote the manuscript, along with R.F., O.B. prepared Table 2, listing the RBPs. L.W. and S.C. contributed to the discussion and writing. All authors have read and agreed to the published version of the manuscript.

Funding

S.V.G. was supported by a post-doctoral fellowship from the Kempe Foundation (SMK1864) and a grant from the Lion’s Cancer Research Foundation (LP 21-2270), Umeå University and Cancerfonden (160598). O.B. was supported by a scholarship from the Wenner-Gren Foundations in Sweden. This work was partially funded by grants from the European Regional Development Fund—Project ENOCH (No. CZ.02.1.01/0.0/0.0/16_019/0000868), the Grant Agency of the Czech Republic (GACR 19-18177Y), and the Ministry of Health, Czech Republic; Conceptual Development of Research Organization (MMCI, 00209805).

Acknowledgments

We apologize to those whose works were not cited in this review owing to space limitations. The nucleic acid illustrations used in the figures were created using Servier Medical Art (smart.servier.com), accessed on 14 July 2021.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Huang, R.X.; Zhou, P.K. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020, 5, 60. [Google Scholar] [CrossRef] [PubMed]
  2. Bauer, N.C.; Corbett, A.H.; Doetsch, P.W. The current state of eukaryotic DNA base damage and repair. Nucleic Acids Res. 2015, 43, 10083–10101. [Google Scholar] [CrossRef]
  3. Williams, A.B.; Schumacher, B. p53 in the DNA-Damage-Repair Process. Cold Spring Harb. Perspect. Med. 2016, 6, a026070. [Google Scholar] [CrossRef] [PubMed]
  4. Li, Z.; Pearlman, A.H.; Hsieh, P. DNA mismatch repair and the DNA damage response. DNA Repair 2016, 38, 94–101. [Google Scholar] [CrossRef] [PubMed]
  5. Ciccia, A.; Elledge, S.J. The DNA damage response: Making it safe to play with knives. Mol. Cell 2010, 40, 179–204. [Google Scholar] [CrossRef]
  6. Huang, X.; Halicka, H.D.; Darzynkiewicz, Z. Detection of histone H2AX phosphorylation on Ser-139 as an indicator of DNA damage (DNA double-strand breaks). Curr. Protoc. Cytom. 2004, 30, 7–27. [Google Scholar] [CrossRef]
  7. Meek, D.W.; Anderson, C.W. Posttranslational modification of p53: Cooperative integrators of function. Cold Spring Harb. Perspect. Biol. 2009, 1, a000950. [Google Scholar] [CrossRef]
  8. Marechal, A.; Zou, L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb. Perspect. Biol. 2013, 5, a012716. [Google Scholar] [CrossRef]
  9. Lanz, M.C.; Dibitetto, D.; Smolka, M.B. DNA damage kinase signaling: Checkpoint and repair at 30 years. EMBO J. 2019, 38, e101801. [Google Scholar] [CrossRef]
  10. Burger, K.; Ketley, R.F.; Gullerova, M. Beyond the Trinity of ATM, ATR, and DNA-PK: Multiple Kinases Shape the DNA Damage Response in Concert With RNA Metabolism. Front. Mol. Biosci. 2019, 6, 61. [Google Scholar] [CrossRef] [PubMed]
  11. Jackson, S.P.; Bartek, J. The DNA-damage response in human biology and disease. Nature 2009, 461, 1071–1078. [Google Scholar] [CrossRef]
  12. Reinhardt, H.C.; Schumacher, B. The p53 network: Cellular and systemic DNA damage responses in aging and cancer. Trends Genet. 2012, 28, 128–136. [Google Scholar] [CrossRef]
  13. Sancar, A.; Lindsey-Boltz, L.A.; Unsal-Kacmaz, K.; Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 2004, 73, 39–85. [Google Scholar] [CrossRef] [PubMed]
  14. Jiricny, J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 2006, 7, 335–346. [Google Scholar] [CrossRef]
  15. David, S.S.; O’Shea, V.L.; Kundu, S. Base-excision repair of oxidative DNA damage. Nature 2007, 447, 941–950. [Google Scholar] [CrossRef] [PubMed]
  16. Chang, H.H.Y.; Pannunzio, N.R.; Adachi, N.; Lieber, M.R. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat. Rev. Mol. Cell Biol. 2017, 18, 495–506. [Google Scholar] [CrossRef]
  17. Zhao, B.; Rothenberg, E.; Ramsden, D.A.; Lieber, M.R. The molecular basis and disease relevance of non-homologous DNA end joining. Nat. Rev. Mol. Cell Biol. 2020, 21, 765–781. [Google Scholar] [CrossRef]
  18. Speidel, D. The role of DNA damage responses in p53 biology. Arch. Toxicol. 2015, 89, 501–517. [Google Scholar] [CrossRef]
  19. Lane, D.P.; Crawford, L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979, 278, 261–263. [Google Scholar] [CrossRef]
  20. Linzer, D.I.; Levine, A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979, 17, 43–52. [Google Scholar] [CrossRef]
  21. Olivier, M.; Hollstein, M.; Hainaut, P. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2, a001008. [Google Scholar] [CrossRef]
  22. Kastenhuber, E.R.; Lowe, S.W. Putting p53 in Context. Cell 2017, 170, 1062–1078. [Google Scholar] [CrossRef]
  23. Gomez-Lazaro, M.; Fernandez-Gomez, F.J.; Jordan, J. p53: Twenty five years understanding the mechanism of genome protection. J. Physiol. Biochem. 2004, 60, 287–307. [Google Scholar] [CrossRef]
  24. Brown, C.J.; Lain, S.; Verma, C.S.; Fersht, A.R.; Lane, D.P. Awakening guardian angels: Drugging the p53 pathway. Nat. Rev. Cancer 2009, 9, 862–873. [Google Scholar] [CrossRef] [PubMed]
  25. Riley, T.; Sontag, E.; Chen, P.; Levine, A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9, 402–412. [Google Scholar] [CrossRef] [PubMed]
  26. Haronikova, L.; Olivares-Illana, V.; Wang, L.; Karakostis, K.; Chen, S.; Fahraeus, R. The p53 mRNA: An integral part of the cellular stress response. Nucleic Acids Res. 2019, 47, 3257–3271. [Google Scholar] [CrossRef]
  27. Olivares-Illana, V.; Fahraeus, R. p53 isoforms gain functions. Oncogene 2010, 29, 5113–5119. [Google Scholar] [CrossRef] [PubMed]
  28. Lane, D.P. Cancer. p53, guardian of the genome. Nature 1992, 358, 15–16. [Google Scholar] [CrossRef] [PubMed]
  29. Vogelstein, B.; Lane, D.; Levine, A.J. Surfing the p53 network. Nature 2000, 408, 307–310. [Google Scholar] [CrossRef]
  30. Bieging, K.T.; Attardi, L.D. Deconstructing p53 transcriptional networks in tumor suppression. Trends Cell Biol. 2012, 22, 97–106. [Google Scholar] [CrossRef]
  31. Bieging, K.T.; Mello, S.S.; Attardi, L.D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 2014, 14, 359–370. [Google Scholar] [CrossRef]
  32. Malkin, D.; Li, F.P.; Strong, L.C.; Fraumeni, J.F., Jr.; Nelson, C.E.; Kim, D.H.; Kassel, J.; Gryka, M.A.; Bischoff, F.Z.; Tainsky, M.A.; et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250, 1233–1238. [Google Scholar] [CrossRef] [PubMed]
  33. Maltzman, W.; Czyzyk, L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell Biol. 1984, 4, 1689–1694. [Google Scholar] [CrossRef] [PubMed]
  34. Kastan, M.B.; Onyekwere, O.; Sidransky, D.; Vogelstein, B.; Craig, R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991, 51, 6304–6311. [Google Scholar] [CrossRef]
  35. Lowe, S.W.; Schmitt, E.M.; Smith, S.W.; Osborne, B.A.; Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993, 362, 847–849. [Google Scholar] [CrossRef] [PubMed]
  36. Fritsche, M.; Haessler, C.; Brandner, G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993, 8, 307–318. [Google Scholar] [PubMed]
  37. Shieh, S.Y.; Ikeda, M.; Taya, Y.; Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91, 325–334. [Google Scholar] [CrossRef]
  38. El-Deiry, W.S.; Tokino, T.; Velculescu, V.E.; Levy, D.B.; Parsons, R.; Trent, J.M.; Lin, D.; Mercer, W.E.; Kinzler, K.W.; Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75, 817–825. [Google Scholar] [CrossRef]
  39. Harper, J.W.; Adami, G.R.; Wei, N.; Keyomarsi, K.; Elledge, S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75, 805–816. [Google Scholar] [CrossRef]
  40. Clarke, A.R.; Purdie, C.A.; Harrison, D.J.; Morris, R.G.; Bird, C.C.; Hooper, M.L.; Wyllie, A.H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993, 362, 849–852. [Google Scholar] [CrossRef] [PubMed]
  41. Yonish-Rouach, E.; Resnitzky, D.; Lotem, J.; Sachs, L.; Kimchi, A.; Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991, 352, 345–347. [Google Scholar] [CrossRef] [PubMed]
  42. Tompa, P. The interplay between structure and function in intrinsically unstructured proteins. FEBS Lett. 2005, 579, 3346–3354. [Google Scholar] [CrossRef]
  43. Olivier, C.; Poirier, G.; Gendron, P.; Boisgontier, A.; Major, F.; Chartrand, P. Identification of a conserved RNA motif essential for She2p recognition and mRNA localization to the yeast bud. Mol. Cell Biol. 2005, 25, 4752–4766. [Google Scholar] [CrossRef]
  44. Candeias, M.M.; Malbert-Colas, L.; Powell, D.J.; Daskalogianni, C.; Maslon, M.M.; Naski, N.; Bourougaa, K.; Calvo, F.; Fahraeus, R. P53 mRNA controls p53 activity by managing Mdm2 functions. Nat. Cell Biol. 2008, 10, 1098–1105. [Google Scholar] [CrossRef]
  45. Song, J.; Perreault, J.P.; Topisirovic, I.; Richard, S. RNA G-quadruplexes and their potential regulatory roles in translation. Translation 2016, 4, e1244031. [Google Scholar] [CrossRef]
  46. Lopez, I.; Tournillon, A.S.; Prado Martins, R.; Karakostis, K.; Malbert-Colas, L.; Nylander, K.; Fahraeus, R. p53-mediated suppression of BiP triggers BIK-induced apoptosis during prolonged endoplasmic reticulum stress. Cell Death Differ. 2017, 24, 1717–1729. [Google Scholar] [CrossRef] [PubMed]
  47. Tournillon, A.S.; Lopez, I.; Malbert-Colas, L.; Findakly, S.; Naski, N.; Olivares-Illana, V.; Karakostis, K.; Vojtesek, B.; Nylander, K.; Fahraeus, R. p53 binds the mdmx mRNA and controls its translation. Oncogene 2017, 36, 723–730. [Google Scholar] [CrossRef]
  48. Gnanasundram, S.V.; Pyndiah, S.; Daskalogianni, C.; Armfield, K.; Nylander, K.; Wilson, J.B.; Fahraeus, R. PI3Kdelta activates E2F1 synthesis in response to mRNA translation stress. Nat. Commun. 2017, 8, 2103. [Google Scholar] [CrossRef]
  49. Vadivel Gnanasundram, S.; Fahraeus, R. Translation Stress Regulates Ribosome Synthesis and Cell Proliferation. Int. J. Mol. Sci. 2018, 19, 3757. [Google Scholar] [CrossRef] [PubMed]
  50. Swiatkowska, A.; Dutkiewicz, M.; Zydowicz-Machtel, P.; Szpotkowska, J.; Janecki, D.M.; Ciesiolka, J. Translational Control in p53 Expression: The Role of 5′-Terminal Region of p53 mRNA. Int. J. Mol. Sci. 2019, 20, 5382. [Google Scholar] [CrossRef]
  51. Mosner, J.; Mummenbrauer, T.; Bauer, C.; Sczakiel, G.; Grosse, F.; Deppert, W. Negative feedback regulation of wild-type p53 biosynthesis. EMBO J. 1995, 14, 4442–4449. [Google Scholar] [CrossRef]
  52. Takagi, M.; Absalon, M.J.; McLure, K.G.; Kastan, M.B. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 2005, 123, 49–63. [Google Scholar] [CrossRef] [PubMed]
  53. Chen, J.; Guo, K.; Kastan, M.B. Interactions of nucleolin and ribosomal protein L26 (RPL26) in translational control of human p53 mRNA. J. Biol. Chem. 2012, 287, 16467–16476. [Google Scholar] [CrossRef] [PubMed]
  54. Chen, J.; Kastan, M.B. 5′-3′-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage. Genes Dev. 2010, 24, 2146–2156. [Google Scholar] [CrossRef] [PubMed]
  55. Yin, Y.; Stephen, C.W.; Luciani, M.G.; Fahraeus, R. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat. Cell Biol. 2002, 4, 462–467. [Google Scholar] [CrossRef] [PubMed]
  56. Courtois, S.; Caron de Fromentel, C.; Hainaut, P. p53 protein variants: Structural and functional similarities with p63 and p73 isoforms. Oncogene 2004, 23, 631–638. [Google Scholar] [CrossRef] [PubMed][Green Version]
  57. Scrable, H.; Sasaki, T.; Maier, B. DeltaNp53 or p44: Priming the p53 pump. Int. J. Biochem. Cell Biol. 2005, 37, 913–919. [Google Scholar] [CrossRef]
  58. Halaby, M.J.; Yang, D.Q. p53 translational control: A new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. Gene 2007, 395, 1–7. [Google Scholar] [CrossRef]
  59. Candeias, M.M.; Powell, D.J.; Roubalova, E.; Apcher, S.; Bourougaa, K.; Vojtesek, B.; Bruzzoni-Giovanelli, H.; Fahraeus, R. Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation. Oncogene 2006, 25, 6936–6947. [Google Scholar] [CrossRef]
  60. Ray, P.S.; Grover, R.; Das, S. Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep. 2006, 7, 404–410. [Google Scholar] [CrossRef]
  61. Yang, D.Q.; Halaby, M.J.; Zhang, Y. The identification of an internal ribosomal entry site in the 5′-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene 2006, 25, 4613–4619. [Google Scholar] [CrossRef] [PubMed]
  62. Wedeken, L.; Singh, P.; Klempnauer, K.H. Tumor suppressor protein Pdcd4 inhibits translation of p53 mRNA. J. Biol. Chem. 2011, 286, 42855–42862. [Google Scholar] [CrossRef] [PubMed]
  63. Zhang, J.; Cho, S.J.; Shu, L.; Yan, W.; Guerrero, T.; Kent, M.; Skorupski, K.; Chen, H.; Chen, X. Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas. Genes Dev. 2011, 25, 1528–1543. [Google Scholar] [CrossRef] [PubMed]
  64. Weingarten-Gabbay, S.; Khan, D.; Liberman, N.; Yoffe, Y.; Bialik, S.; Das, S.; Oren, M.; Kimchi, A. The translation initiation factor DAP5 promotes IRES-driven translation of p53 mRNA. Oncogene 2014, 33, 611–618. [Google Scholar] [CrossRef] [PubMed]
  65. Halaby, M.J.; Li, Y.; Harris, B.R.; Jiang, S.; Miskimins, W.K.; Cleary, M.P.; Yang, D.Q. Translational Control Protein 80 Stimulates IRES-Mediated Translation of p53 mRNA in Response to DNA Damage. Biomed. Res. Int. 2015, 2015, 708158. [Google Scholar] [CrossRef]
  66. Lamaa, A.; Le Bras, M.; Skuli, N.; Britton, S.; Frit, P.; Calsou, P.; Prats, H.; Cammas, A.; Millevoi, S. A novel cytoprotective function for the DNA repair protein Ku in regulating p53 mRNA translation and function. EMBO Rep. 2016, 17, 508–518. [Google Scholar] [CrossRef]
  67. Christian, K.J.; Lang, M.A.; Raffalli-Mathieu, F. Interaction of heterogeneous nuclear ribonucleoprotein C1/C2 with a novel cis-regulatory element within p53 mRNA as a response to cytostatic drug treatment. Mol. Pharmacol. 2008, 73, 1558–1567. [Google Scholar] [CrossRef]
  68. Seo, J.Y.; Kim, D.Y.; Kim, S.H.; Kim, H.J.; Ryu, H.G.; Lee, J.; Lee, K.H.; Kim, K.T. Heterogeneous nuclear ribonucleoprotein (hnRNP) L promotes DNA damage-induced cell apoptosis by enhancing the translation of p53. Oncotarget 2017, 8, 51108–51122. [Google Scholar] [CrossRef]
  69. Kim, D.Y.; Kim, W.; Lee, K.H.; Kim, S.H.; Lee, H.R.; Kim, H.J.; Jung, Y.; Choi, J.H.; Kim, K.T. hnRNP Q regulates translation of p53 in normal and stress conditions. Cell Death Differ. 2013, 20, 226–234. [Google Scholar] [CrossRef]
  70. Fu, L.; Benchimol, S. Participation of the human p53 3′UTR in translational repression and activation following gamma-irradiation. EMBO J. 1997, 16, 4117–4125. [Google Scholar] [CrossRef]
  71. Fu, L.; Ma, W.; Benchimol, S. A translation repressor element resides in the 3′ untranslated region of human p53 mRNA. Oncogene 1999, 18, 6419–6424. [Google Scholar] [CrossRef] [PubMed]
  72. Mazan-Mamczarz, K.; Galban, S.; Lopez de Silanes, I.; Martindale, J.L.; Atasoy, U.; Keene, J.D.; Gorospe, M. RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc. Natl. Acad. Sci. USA 2003, 100, 8354–8359. [Google Scholar] [CrossRef] [PubMed]
  73. Abdelmohsen, K.; Panda, A.C.; Kang, M.J.; Guo, R.; Kim, J.; Grammatikakis, I.; Yoon, J.H.; Dudekula, D.B.; Noh, J.H.; Yang, X.; et al. 7SL RNA represses p53 translation by competing with HuR. Nucleic Acids Res. 2014, 42, 10099–10111. [Google Scholar] [CrossRef] [PubMed]
  74. Ahuja, D.; Goyal, A.; Ray, P.S. Interplay between RNA-binding protein HuR and microRNA-125b regulates p53 mRNA translation in response to genotoxic stress. RNA Biol. 2016, 13, 1152–1165. [Google Scholar] [CrossRef] [PubMed]
  75. Katoch, A.; George, B.; Iyyappan, A.; Khan, D.; Das, S. Interplay between PTB and miR-1285 at the p53 3′UTR modulates the levels of p53 and its isoform Delta40p53alpha. Nucleic Acids Res. 2017, 45, 10206–10217. [Google Scholar] [CrossRef]
  76. Devany, E.; Zhang, X.; Park, J.Y.; Tian, B.; Kleiman, F.E. Positive and negative feedback loops in the p53 and mRNA 3′ processing pathways. Proc. Natl. Acad. Sci. USA 2013, 110, 3351–3356. [Google Scholar] [CrossRef] [PubMed]
  77. Grover, R.; Ray, P.S.; Das, S. Polypyrimidine tract binding protein regulates IRES-mediated translation of p53 isoforms. Cell Cycle 2008, 7, 2189–2198. [Google Scholar] [CrossRef]
  78. Gajjar, M.; Candeias, M.M.; Malbert-Colas, L.; Mazars, A.; Fujita, J.; Olivares-Illana, V.; Fahraeus, R. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell 2012, 21, 25–35. [Google Scholar] [CrossRef]
  79. Malbert-Colas, L.; Ponnuswamy, A.; Olivares-Illana, V.; Tournillon, A.S.; Naski, N.; Fahraeus, R. HDMX folds the nascent p53 mRNA following activation by the ATM kinase. Mol. Cell 2014, 54, 500–511. [Google Scholar] [CrossRef]
  80. Diaz-Munoz, M.D.; Kiselev, V.Y.; Le Novere, N.; Curk, T.; Ule, J.; Turner, M. Tia1 dependent regulation of mRNA subcellular location and translation controls p53 expression in B cells. Nat. Commun. 2017, 8, 530. [Google Scholar] [CrossRef]
  81. Lin, C.C.; Liao, W.T.; Yang, T.Y.; Lu, H.J.; Hsu, S.L.; Wu, C.C. MicroRNA10b modulates cisplatin tolerance by targeting p53 directly in lung cancer cells. Oncol. Rep. 2021, 46, 167. [Google Scholar] [CrossRef] [PubMed]
  82. Newman, M.; Sfaxi, R.; Saha, A.; Monchaud, D.; Teulade-Fichou, M.P.; Vagner, S. The G-Quadruplex-Specific RNA Helicase DHX36 Regulates p53 Pre-mRNA 3′-End Processing Following UV-Induced DNA Damage. J. Mol. Biol. 2017, 429, 3121–3131. [Google Scholar] [CrossRef]
  83. Decorsiere, A.; Cayrel, A.; Vagner, S.; Millevoi, S. Essential role for the interaction between hnRNP H/F and a G quadruplex in maintaining p53 pre-mRNA 3′-end processing and function during DNA damage. Genes Dev. 2011, 25, 220–225. [Google Scholar] [CrossRef]
  84. Mitschka, S.; Mayr, C. Endogenous p53 expression in human and mouse is not regulated by its 3′UTR. eLife 2021, 10, e65700. [Google Scholar] [CrossRef] [PubMed]
  85. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387, 296–299. [Google Scholar] [CrossRef] [PubMed]
  86. Kubbutat, M.H.; Jones, S.N.; Vousden, K.H. Regulation of p53 stability by Mdm2. Nature 1997, 387, 299–303. [Google Scholar] [CrossRef] [PubMed]
  87. Naski, N.; Gajjar, M.; Bourougaa, K.; Malbert-Colas, L.; Fahraeus, R.; Candeias, M.M. The p53 mRNA-Mdm2 interaction. Cell Cycle 2009, 8, 31–34. [Google Scholar] [CrossRef] [PubMed]
  88. Medina-Medina, I.; Garcia-Beltran, P.; de la Mora, I.; Oria-Hernandez, J.; Millot, G.; Fahraeus, R.; Reyes-Vivas, H.; Sampedro, J.G.; Olivares-Illana, V. Allosteric Interactions by p53 mRNA Govern HDM2 E3 Ubiquitin Ligase Specificity under Different Conditions. Mol. Cell Biol. 2016, 36, 2195–2205. [Google Scholar] [CrossRef]
  89. Pereg, Y.; Shkedy, D.; de Graaf, P.; Meulmeester, E.; Edelson-Averbukh, M.; Salek, M.; Biton, S.; Teunisse, A.F.; Lehmann, W.D.; Jochemsen, A.G.; et al. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc. Natl. Acad. Sci. USA 2005, 102, 5056–5061. [Google Scholar] [CrossRef] [PubMed]
  90. Karakostis, K.; Ponnuswamy, A.; Fusee, L.T.; Bailly, X.; Laguerre, L.; Worall, E.; Vojtesek, B.; Nylander, K.; Fahraeus, R. p53 mRNA and p53 Protein Structures Have Evolved Independently to Interact with MDM2. Mol. Biol. Evol. 2016, 33, 1280–1292. [Google Scholar] [CrossRef] [PubMed]
  91. Karakostis, K.; Fahraeus, R. Shaping the regulation of the p53 mRNA tumour suppressor: The co-evolution of genetic signatures. BMC Cancer 2019, 19, 915. [Google Scholar] [CrossRef]
  92. Karakostis, K.; Vadivel Gnanasundram, S.; Lopez, I.; Thermou, A.; Wang, L.; Nylander, K.; Olivares-Illana, V.; Fahraeus, R. A single synonymous mutation determines the phosphorylation and stability of the nascent protein. J. Mol. Cell Biol. 2019, 11, 187–199. [Google Scholar] [CrossRef] [PubMed]
  93. Kai, M. Roles of RNA-Binding Proteins in DNA Damage Response. Int. J. Mol. Sci. 2016, 17, 310. [Google Scholar] [CrossRef] [PubMed]
  94. Dutertre, M.; Lambert, S.; Carreira, A.; Amor-Gueret, M.; Vagner, S. DNA damage: RNA-binding proteins protect from near and far. Trends Biochem. Sci. 2014, 39, 141–149. [Google Scholar] [CrossRef] [PubMed]
  95. Dutertre, M.; Vagner, S. DNA-Damage Response RNA-Binding Proteins (DDRBPs): Perspectives from a New Class of Proteins and Their RNA Targets. J. Mol. Biol. 2017, 429, 3139–3145. [Google Scholar] [CrossRef] [PubMed]
  96. Hu, X.; Li, Y.; Zhang, T.; Li, L.; Chen, S.; Wu, X.; Li, H.; Qi, B.; Chen, Z. Phosphorylation of Ago2 is required for its role in DNA double-strand break repair. J. Genet. Genom. 2021, 48, 333–340. [Google Scholar] [CrossRef] [PubMed]
  97. Li, X.; Wang, X.; Cheng, Z.; Zhu, Q. AGO2 and its partners: A silencing complex, a chromatin modulator, and new features. Crit. Rev. Biochem. Mol. Biol. 2020, 55, 33–53. [Google Scholar] [CrossRef] [PubMed]
  98. Krell, J.; Stebbing, J.; Carissimi, C.; Dabrowska, A.F.; de Giorgio, A.; Frampton, A.E.; Harding, V.; Fulci, V.; Macino, G.; Colombo, T.; et al. TP53 regulates miRNA association with AGO2 to remodel the miRNA-mRNA interaction network. Genome Res. 2016, 2016. 26, 331–341. [Google Scholar] [CrossRef]
  99. Ouchi, T.; Monteiro, A.N.A.; August, A.; Aaronson, S.A.; Hanafusa, H. BRCA1 regulates p53-dependent gene expression. Proc. Natl. Acad. Sci. USA 1998, 95, 2302–2306. [Google Scholar] [CrossRef]
  100. Yoshida, K.; Miki, Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004, 95, 866–871. [Google Scholar] [CrossRef] [PubMed]
  101. Wang, B.; Matsuoka, S.; Ballif, B.A.; Zhang, D.; Smogorzewska, A.; Gygi, S.P.; Elledge, S.J. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007, 316, 1194–1198. [Google Scholar] [CrossRef]
  102. Feng, L.; Huang, J.; Chen, J. MERIT40 facilitates BRCA1 localization and DNA damage repair. Genes Dev. 2009, 23, 719–728. [Google Scholar] [CrossRef] [PubMed]
  103. Johnson, G.S.; Rajendran, P.; Dashwood, R.H. CCAR1 and CCAR2 as gene chameleons with antagonistic duality: Preclinical, human translational, and mechanistic basis. Cancer Sci. 2020, 111, 3416–3425. [Google Scholar] [CrossRef] [PubMed]
  104. Magni, M.; Buscemi, G.; Zannini, L. Cell cycle and apoptosis regulator 2 at the interface between DNA damage response and cell physiology. Mutat. Res. Rev. Mutat. Res. 2018, 776, 1–9. [Google Scholar] [CrossRef] [PubMed]
  105. Nicol, S.M.; Bray, S.E.; Black, H.D.; Lorimore, S.A.; Wright, E.G.; Lane, D.P.; Meek, D.W.; Coates, P.J.; Fuller-Pace, F.V. The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell-cycle arrest after DNA damage. Oncogene 2013, 32, 3461–3469. [Google Scholar] [CrossRef] [PubMed]
  106. Yu, Z.; Mersaoui, S.Y.; Guitton-Sert, L.; Coulombe, Y.; Song, J.; Masson, J.Y.; Richard, S. DDX5 resolves R-loops at DNA double-strand breaks to promote DNA repair and avoid chromosomal deletions. NAR Cancer 2020, 2, zcaa028. [Google Scholar] [CrossRef] [PubMed]
  107. Halaby, M.J.; Harris, B.R.; Miskimins, W.K.; Cleary, M.P.; Yang, D.Q. Deregulation of Internal Ribosome Entry Site-Mediated p53 Translation in Cancer Cells with Defective p53 Response to DNA Damage. Mol. Cell Biol. 2015, 35, 4006–4017. [Google Scholar] [CrossRef] [PubMed]
  108. Hong, Z.; Jiang, J.; Ma, J.; Dai, S.; Xu, T.; Li, H.; Yasui, A. The role of hnRPUL1 involved in DNA damage response is related to PARP1. PLoS ONE 2013, 8, e60208. [Google Scholar] [CrossRef]
  109. Polo, S.E.; Blackford, A.N.; Chapman, J.R.; Baskcomb, L.; Gravel, S.; Rusch, A.; Thomas, A.; Blundred, R.; Smith, P.; Kzhyshkowska, J. Regulation of DNA-end resection by hnRNPU-like proteins promotes DNA double-strand break signaling and repair. Mol. Cell 2012, 45, 505–516. [Google Scholar] [CrossRef]
  110. Kim, H.H.; Abdelmohsen, K.; Gorospe, M. Regulation of HuR by DNA Damage Response Kinases. J. Nucleic Acids 2010, 2010, 981487. [Google Scholar] [CrossRef]
  111. Mohammadi, E.; Sadoughi, F.; Younesi, S.; Karimian, A.; Asemi, Z.; Farsad-Akhtar, N.; Jahanbakhshi, F.; Jamilian, H.; Yousefi, B. The molecular mechanism of nuclear signaling for degradation of cytoplasmic DNA: Importance in DNA damage response and cancer. DNA Repair 2021, 103, 103115. [Google Scholar] [CrossRef]
  112. Chaplin, A.K.; Hardwick, S.W.; Liang, S.; Kefala Stavridi, A.; Hnizda, A.; Cooper, L.R.; De Oliveira, T.M.; Chirgadze, D.Y.; Blundell, T.L. Dimers of DNA-PK create a stage for DNA double-strand break repair. Nat. Struct. Mol. Biol. 2021, 28, 13–19. [Google Scholar] [CrossRef]
  113. Kragelund, B.B.; Weterings, E.; Hartmann-Petersen, R.; Keijzers, G. The Ku70/80 ring in Non-Homologous End-Joining: Easy to slip on, hard to remove. Front. Biosci. 2016, 21, 514–527. [Google Scholar] [CrossRef]
  114. Yue, X.; Bai, C.; Xie, D.; Ma, T.; Zhou, P.K. DNA-PKcs: A Multi-Faceted Player in DNA Damage Response. Front. Genet. 2020, 11, 607428. [Google Scholar] [CrossRef]
  115. Haronikova, L.; Vojtesek, B. HDM2 and HDMX Proteins in Human Cancer. Klin. Onkol. 2018, 31, 63–70. [Google Scholar] [CrossRef] [PubMed]
  116. Kim, J.Y.; Seok, K.O.; Kim, Y.J.; Bae, W.K.; Lee, S.; Park, J.H. Involvement of GLTSCR2 in the DNA Damage Response. Am. J. Pathol. 2011, 179, 1257–1264. [Google Scholar] [CrossRef] [PubMed]
  117. Lee, S.; Cho, Y.E.; Kim, Y.J.; Park, J.H. c-Jun N-terminal kinase regulates the nucleoplasmic translocation and stability of nucleolar GLTSCR2 protein. Biochem. Biophys. Res. Commun. 2016, 472, 95–100. [Google Scholar] [CrossRef] [PubMed]
  118. Lee, S.; Kim, J.Y.; Kim, Y.J.; Seok, K.O.; Kim, J.H.; Chang, Y.J.; Kang, H.Y.; Park, J.H. Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal stresses. Cell Death Differ. 2012, 19, 1613–1622. [Google Scholar] [CrossRef]
  119. Zhu, J.; Chen, X. MCG10, a novel p53 target gene that encodes a KH domain RNA-binding protein, is capable of inducing apoptosis and cell cycle arrest in G(2)-M. Mol. Cell Biol. 2000, 20, 5602–5618. [Google Scholar] [CrossRef]
  120. Scoumanne, A.; Cho, S.J.; Zhang, J.; Chen, X. The cyclin-dependent kinase inhibitor p21 is regulated by RNA-binding protein PCBP4 via mRNA stability. Nucleic Acids Res. 2011, 39, 213–224. [Google Scholar] [CrossRef] [PubMed]
  121. Xu, E.; Zhang, J.; Chen, X. MDM2 expression is repressed by the RNA-binding protein RNPC1 via mRNA stability. Oncogene 2013, 32, 2169–2178. [Google Scholar] [CrossRef][Green Version]
  122. Shin, K.H.; Kim, R.H.; Kang, M.K.; Kim, R.H.; Kim, S.G.; Lim, P.K.; Yochim, J.M.; Baluda, M.A.; Park, N.H. p53 promotes the fidelity of DNA end-joining activity by, in part, enhancing the expression of heterogeneous nuclear ribonucleoprotein G. DNA Repair 2007, 6, 830–840. [Google Scholar] [CrossRef]
  123. Adamson, B.; Smogorzewska, A.; Sigoillot, F.D.; King, R.W.; Elledge, S.J. A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. Nat. Cell Biol. 2012, 14, 318–328. [Google Scholar] [CrossRef]
  124. Xiong, X.; Zhao, Y.; He, H.; Sun, Y. Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator. Oncogene 2011, 30, 1798–1811. [Google Scholar] [CrossRef]
  125. Zhao, Y.; Tan, M.; Liu, X.; Xiong, X.; Sun, Y. Inactivation of ribosomal protein S27-like confers radiosensitivity via the Mdm2-p53 and Mdm2-MRN-ATM axes. Cell Death Dis. 2018, 9, 145. [Google Scholar] [CrossRef]
  126. Shah, A.; Lindquist, J.A.; Rosendahl, L.; Schmitz, I.; Mertens, P.R. Novel Insights into YB-1 Signaling and Cell Death Decisions. Cancers 2021, 13, 3306. [Google Scholar] [CrossRef]
  127. Sangermano, F.; Delicato, A.; Calabro, V. Y box binding protein 1 (YB-1) oncoprotein at the hub of DNA proliferation, damage and cancer progression. Biochimie 2020, 179, 205–216. [Google Scholar] [CrossRef]
  128. Dutertre, M.; Sanchez, G.; De Cian, M.C.; Barbier, J.; Dardenne, E.; Gratadou, L.; Dujardin, G.; Le Jossic-Corcos, C.; Corcos, L.; Auboeuf, D.; et al. Cotranscriptional exon skipping in the genotoxic stress response. Nat. Struct. Mol. Biol 2010, 17, 1358–1366. [Google Scholar] [CrossRef]
  129. Bader, A.S.; Hawley, B.R.; Wilczynska, A.; Bushell, M. The roles of RNA in DNA double-strand break repair. Br. J. Cancer 2020, 122, 613–623. [Google Scholar] [CrossRef]
  130. Wang, I.X.; Grunseich, C.; Fox, J.; Burdick, J.; Zhu, Z.; Ravazian, N.; Hafner, M.; Cheung, V.G. Human proteins that interact with RNA/DNA hybrids. Genome Res. 2018, 28, 1405–1414. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.